Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19021058 | Prostate | BPH | regulation of leukocyte differentiation | 71/3107 | 279/18723 | 9.94e-05 | 9.21e-04 | 71 |
GO:00026839 | Prostate | BPH | negative regulation of immune system process | 100/3107 | 434/18723 | 2.83e-04 | 2.20e-03 | 100 |
GO:00510906 | Prostate | BPH | regulation of DNA-binding transcription factor activity | 100/3107 | 440/18723 | 4.71e-04 | 3.37e-03 | 100 |
GO:00072547 | Prostate | BPH | JNK cascade | 45/3107 | 167/18723 | 4.74e-04 | 3.39e-03 | 45 |
GO:00330023 | Prostate | BPH | muscle cell proliferation | 61/3107 | 248/18723 | 7.61e-04 | 5.02e-03 | 61 |
GO:00486605 | Prostate | BPH | regulation of smooth muscle cell proliferation | 47/3107 | 180/18723 | 7.63e-04 | 5.03e-03 | 47 |
GO:003249615 | Prostate | BPH | response to lipopolysaccharide | 79/3107 | 343/18723 | 1.18e-03 | 7.29e-03 | 79 |
GO:00486595 | Prostate | BPH | smooth muscle cell proliferation | 47/3107 | 184/18723 | 1.26e-03 | 7.62e-03 | 47 |
GO:00148122 | Prostate | BPH | muscle cell migration | 31/3107 | 110/18723 | 1.56e-03 | 9.16e-03 | 31 |
GO:00027615 | Prostate | BPH | regulation of myeloid leukocyte differentiation | 33/3107 | 120/18723 | 1.76e-03 | 1.01e-02 | 33 |
GO:00456399 | Prostate | BPH | positive regulation of myeloid cell differentiation | 29/3107 | 103/18723 | 2.20e-03 | 1.22e-02 | 29 |
GO:0045638 | Prostate | BPH | negative regulation of myeloid cell differentiation | 26/3107 | 90/18723 | 2.46e-03 | 1.33e-02 | 26 |
GO:000223715 | Prostate | BPH | response to molecule of bacterial origin | 81/3107 | 363/18723 | 2.63e-03 | 1.41e-02 | 81 |
GO:00149093 | Prostate | BPH | smooth muscle cell migration | 27/3107 | 97/18723 | 3.65e-03 | 1.85e-02 | 27 |
GO:19021074 | Prostate | BPH | positive regulation of leukocyte differentiation | 38/3107 | 157/18723 | 8.96e-03 | 3.83e-02 | 38 |
GO:19037084 | Prostate | BPH | positive regulation of hemopoiesis | 38/3107 | 157/18723 | 8.96e-03 | 3.83e-02 | 38 |
GO:007121610 | Prostate | BPH | cellular response to biotic stimulus | 55/3107 | 246/18723 | 1.11e-02 | 4.55e-02 | 55 |
GO:004217619 | Prostate | Tumor | regulation of protein catabolic process | 142/3246 | 391/18723 | 9.32e-20 | 5.79e-17 | 142 |
GO:001049819 | Prostate | Tumor | proteasomal protein catabolic process | 158/3246 | 490/18723 | 3.05e-16 | 6.76e-14 | 158 |
GO:000989619 | Prostate | Tumor | positive regulation of catabolic process | 155/3246 | 492/18723 | 5.62e-15 | 8.52e-13 | 155 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRIB1 | SNV | Missense_Mutation | | c.616N>G | p.Leu206Val | p.L206V | Q96RU8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TRIB1 | SNV | Missense_Mutation | | c.1015N>A | p.Glu339Lys | p.E339K | Q96RU8 | protein_coding | tolerated(0.45) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
TRIB1 | SNV | Missense_Mutation | rs138022510 | c.947G>A | p.Arg316His | p.R316H | Q96RU8 | protein_coding | deleterious(0.03) | probably_damaging(0.986) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
TRIB1 | SNV | Missense_Mutation | | c.424N>C | p.Asn142His | p.N142H | Q96RU8 | protein_coding | tolerated(0.53) | benign(0.115) | TCGA-B6-A0RS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.565_566insACCC | p.Ile189AsnfsTer22 | p.I189Nfs*22 | Q96RU8 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIB1 | insertion | Nonsense_Mutation | novel | c.566_567insTTGGGTATTTGCAAGTCTAGAGCTTTAGG | p.Val190TrpfsTer9 | p.V190Wfs*9 | Q96RU8 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.742_743insCTTGTAAGCTCCAGCATTATGAATACTATTTGGGGCTTTGCCTC | p.Tyr248SerfsTer17 | p.Y248Sfs*17 | Q96RU8 | protein_coding | | | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TRIB1 | insertion | Frame_Shift_Ins | novel | c.507dupC | p.Tyr170LeufsTer40 | p.Y170Lfs*40 | Q96RU8 | protein_coding | | | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TRIB1 | SNV | Missense_Mutation | novel | c.974N>G | p.Glu325Gly | p.E325G | Q96RU8 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TRIB1 | SNV | Missense_Mutation | rs776955393 | c.1039A>G | p.Ile347Val | p.I347V | Q96RU8 | protein_coding | tolerated(0.54) | benign(0) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |